10x Genomics Inc (TXG) Stock: A Review of the Recent Movement

The stock of 10x Genomics Inc (TXG) has gone up by 0.28% for the week, with a -18.84% drop in the past month and a -33.06% drop in the past quarter. The volatility ratio for the week is 3.01%, and the volatility levels for the past 30 days are 4.03% for TXG. The simple moving average for the past 20 days is -4.67% for TXG’s stock, with a -22.59% simple moving average for the past 200 days.

Is It Worth Investing in 10x Genomics Inc (NASDAQ: TXG) Right Now?

Moreover, the 36-month beta value for TXG is 1.89. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


The public float for TXG is 98.01M and currently, short sellers hold a 8.75% of that float. On April 04, 2024, TXG’s average trading volume was 1.43M shares.

TXG) stock’s latest price update

10x Genomics Inc (NASDAQ: TXG) has seen a rise in its stock price by 0.66 in relation to its previous close of 36.11. However, the company has experienced a 0.28% gain in its stock price over the last five trading sessions. InvestorPlace reported 2024-03-01 that The U.S. spends approximately $450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost $20 trillion over their lifetime.

Analysts’ Opinion of TXG

Many brokerage firms have already submitted their reports for TXG stocks, with Guggenheim repeating the rating for TXG by listing it as a “Buy.” The predicted price for TXG in the upcoming period, according to Guggenheim is $60 based on the research report published on December 14, 2023 of the previous year 2023.

Wolfe Research, on the other hand, stated in their research note that they expect to see TXG reach a price target of $55. The rating they have provided for TXG stocks is “Outperform” according to the report published on December 13th, 2023.

BofA Securities gave a rating of “Neutral” to TXG, setting the target price at $54 in the report published on December 12th of the previous year.

TXG Trading at -14.54% from the 50-Day Moving Average

After a stumble in the market that brought TXG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.82% of loss for the given period.

Volatility was left at 4.03%, however, over the last 30 days, the volatility rate increased by 3.01%, as shares sank -16.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.78% lower at present.

During the last 5 trading sessions, TXG rose by +0.28%, which changed the moving average for the period of 200-days by -38.10% in comparison to the 20-day moving average, which settled at $37.78. In addition, 10x Genomics Inc saw -35.04% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TXG starting from Saxonov Serge, who sale 4,660 shares at the price of $44.00 back on Mar 04 ’24. After this action, Saxonov Serge now owns 842,900 shares of 10x Genomics Inc, valued at $205,021 using the latest closing price.

Saxonov Serge, the Chief Executive Officer of 10x Genomics Inc, sale 2,821 shares at $46.34 during a trade that took place back on Feb 22 ’24, which means that Saxonov Serge is holding 847,560 shares at $130,737 based on the most recent closing price.

Stock Fundamentals for TXG

Current profitability levels for the company are sitting at:

  • -0.4 for the present operating margin
  • 0.65 for the gross margin

The net margin for 10x Genomics Inc stands at -0.41. The total capital return value is set at -0.29. Equity return is now at value -32.98, with -25.59 for asset returns.

Based on 10x Genomics Inc (TXG), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -0.16. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is -7447.0.

Currently, EBITDA for the company is -158.25 million with net debt to EBITDA at 1.17. When we switch over and look at the enterprise to sales, we see a ratio of 6.58. The receivables turnover for the company is 5.39for trailing twelve months and the total asset turnover is 0.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.69.


To wrap up, the performance of 10x Genomics Inc (TXG) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts